PT3362477T - Proteínas de ligação a antigénio que ativam o recetor de leptina - Google Patents

Proteínas de ligação a antigénio que ativam o recetor de leptina

Info

Publication number
PT3362477T
PT3362477T PT167850726T PT16785072T PT3362477T PT 3362477 T PT3362477 T PT 3362477T PT 167850726 T PT167850726 T PT 167850726T PT 16785072 T PT16785072 T PT 16785072T PT 3362477 T PT3362477 T PT 3362477T
Authority
PT
Portugal
Prior art keywords
antigen
activate
binding proteins
leptin receptor
leptin
Prior art date
Application number
PT167850726T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57184864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3362477(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT3362477T publication Critical patent/PT3362477T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT167850726T 2015-10-12 2016-10-11 Proteínas de ligação a antigénio que ativam o recetor de leptina PT3362477T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562240021P 2015-10-12 2015-10-12
US201662359757P 2016-07-08 2016-07-08
US201662375495P 2016-08-16 2016-08-16
US201662393143P 2016-09-12 2016-09-12

Publications (1)

Publication Number Publication Date
PT3362477T true PT3362477T (pt) 2022-03-02

Family

ID=57184864

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167850726T PT3362477T (pt) 2015-10-12 2016-10-11 Proteínas de ligação a antigénio que ativam o recetor de leptina

Country Status (31)

Country Link
US (6) US10023644B2 (enExample)
EP (2) EP4071173A1 (enExample)
JP (5) JP7034068B2 (enExample)
KR (2) KR20180070609A (enExample)
CN (1) CN108368177B (enExample)
AU (2) AU2016338851B2 (enExample)
CA (1) CA3000215A1 (enExample)
CL (2) CL2018000946A1 (enExample)
CO (1) CO2018003852A2 (enExample)
CY (1) CY1125102T1 (enExample)
DK (1) DK3362477T3 (enExample)
EA (1) EA201890928A1 (enExample)
ES (1) ES2908574T3 (enExample)
HR (1) HRP20220426T8 (enExample)
HU (1) HUE058280T2 (enExample)
IL (3) IL316563A (enExample)
LT (1) LT3362477T (enExample)
MX (2) MX2018004531A (enExample)
MY (1) MY187975A (enExample)
PH (1) PH12018500663A1 (enExample)
PL (1) PL3362477T3 (enExample)
PT (1) PT3362477T (enExample)
RS (1) RS63061B1 (enExample)
SG (1) SG10201913432RA (enExample)
SI (1) SI3362477T1 (enExample)
SM (1) SMT202200125T1 (enExample)
TW (3) TW202417497A (enExample)
UA (1) UA124419C2 (enExample)
UY (1) UY36942A (enExample)
WO (1) WO2017066204A1 (enExample)
ZA (1) ZA201801975B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635527B (zh) 2015-03-10 2021-04-23 里珍纳龙药品有限公司 无菌刺穿系统和方法
TW202417497A (zh) * 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
US10550192B2 (en) * 2016-11-08 2020-02-04 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
CA3055583A1 (en) 2017-05-05 2018-11-08 Regeneron Pharmaceuticals, Inc. Auto-injector
AU2018390811A1 (en) 2017-12-18 2020-07-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
KR102710528B1 (ko) * 2018-10-11 2024-09-27 스미또모 가가꾸 가부시키가이샤 프로필렌옥사이드 정제 장치, 및, 프로필렌옥사이드의 제조방법
CN113424060B (zh) * 2019-01-31 2024-11-26 美国西门子医学诊断股份有限公司 抗纳洛酮和抗纳曲酮单克隆抗体及其生产和使用方法
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
GB2600273B (en) * 2019-07-02 2024-06-05 Univ Shanghai Technology Antibody to leptin receptor
CN114746848B (zh) 2019-12-03 2023-08-04 美光科技公司 用于存储装置的高速缓存架构
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US20220098313A1 (en) * 2020-09-15 2022-03-31 Regeneron Pharmaceuticals, Inc. Use of LEPR Agonists for Pain
HRP20251599T1 (hr) 2021-02-22 2026-01-30 Regeneron Pharmaceuticals, Inc. Postupak za dijagnosticiranje i liječenje parcijalne lipodistrofije
CN114456124B (zh) * 2021-12-30 2023-04-21 华南农业大学 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用
KR20260025363A (ko) 2023-06-16 2026-02-24 리제너론 파아마슈티컬스, 인크. 의료 디바이스 패키징 및 관련 방법
US20250108173A1 (en) 2023-10-02 2025-04-03 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
JP2025148269A (ja) 2024-03-15 2025-10-07 イーライ リリー アンド カンパニー 肥満を治療するための単独又は併用療法としてのレプチン受容体アゴニスト抗体
WO2025227054A1 (en) * 2024-04-25 2025-10-30 The Board Of Regents Of The University Of Texas System Monoclonal antibodies binding to leptin and uses thereof
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
DE69734443T2 (de) 1996-01-08 2006-07-13 Genentech, Inc., South San Francisco Ob-rezeptor und liganden
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
ATE320479T1 (de) 1996-01-23 2006-04-15 Indevus Pharmaceuticals Inc Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
AU2002359288B2 (en) 2001-10-22 2008-07-31 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
IL162269A0 (en) * 2001-12-05 2005-11-20 Baylor College Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US7575878B2 (en) 2004-11-18 2009-08-18 Vib Vzw Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
WO2009045900A2 (en) 2007-09-28 2009-04-09 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing diseases associated with low bone mass
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP2672999A2 (en) 2011-02-10 2013-12-18 Roche Glycart AG Improved immunotherapy
ME03732B (me) 2011-02-25 2021-01-20 Regeneron Pharma Miševi s ADAM6
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
HRP20192255T1 (hr) 2011-08-05 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanizirani miševi s univerzalnim lakim lancem
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
CN104582476B (zh) 2012-06-05 2017-03-08 瑞泽恩制药公司 使用共同轻链制备完全人双特异性抗体的方法
SI2895513T1 (sl) 2012-09-12 2018-11-30 Genzyme Corporation Polipeptidi, ki vsebujejo FC, s spremenjeno glikozilacijo in zmanjšano efektorsko funkcijo
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US20170051062A1 (en) 2014-02-18 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
US10550192B2 (en) 2016-11-08 2020-02-04 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
CN107760761A (zh) 2017-11-10 2018-03-06 江苏省农业科学院 一种加强瘦素激发lepr信号转导的方法
AU2018390811A1 (en) 2017-12-18 2020-07-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia

Also Published As

Publication number Publication date
US10618968B2 (en) 2020-04-14
NZ780753A (en) 2025-06-27
EP3362477A1 (en) 2018-08-22
HK1254862A1 (zh) 2019-07-26
EP4071173A1 (en) 2022-10-12
UA124419C2 (uk) 2021-09-15
JP7436603B2 (ja) 2024-02-21
SI3362477T1 (sl) 2022-04-29
JP7699191B2 (ja) 2025-06-26
JP2024042114A (ja) 2024-03-27
TWI752920B (zh) 2022-01-21
IL258448A (en) 2018-05-31
LT3362477T (lt) 2022-03-10
US20250051465A1 (en) 2025-02-13
PH12018500663A1 (en) 2018-10-01
KR20250069979A (ko) 2025-05-20
NZ780754A (en) 2025-06-27
JP7034068B2 (ja) 2022-03-11
AU2016338851B2 (en) 2023-08-10
HRP20220426T1 (hr) 2022-05-27
KR20180070609A (ko) 2018-06-26
AU2016338851A1 (en) 2018-04-19
HUE058280T2 (hu) 2022-07-28
US20200031946A1 (en) 2020-01-30
IL300961A (en) 2023-04-01
CA3000215A1 (en) 2017-04-20
AU2023206125A1 (en) 2023-08-31
BR112018007318A2 (en) 2018-10-23
MY187975A (en) 2021-11-05
NZ741097A (en) 2025-06-27
WO2017066204A1 (en) 2017-04-20
IL300961B2 (en) 2025-04-01
US20220112293A1 (en) 2022-04-14
US20180282420A1 (en) 2018-10-04
CL2019001434A1 (es) 2019-10-11
US20170101477A1 (en) 2017-04-13
US12275792B2 (en) 2025-04-15
CN108368177A (zh) 2018-08-03
US10253102B2 (en) 2019-04-09
ZA201801975B (en) 2020-07-29
JP2021090461A (ja) 2021-06-17
JP2018535948A (ja) 2018-12-06
CN108368177B (zh) 2022-05-31
TWI824372B (zh) 2023-12-01
RS63061B1 (sr) 2022-04-29
SMT202200125T1 (it) 2022-05-12
TW201726737A (zh) 2017-08-01
US20180282421A1 (en) 2018-10-04
EP3362477B1 (en) 2022-01-05
PL3362477T3 (pl) 2022-05-02
SG10201913432RA (en) 2020-03-30
IL300961B1 (en) 2024-12-01
JP2023002713A (ja) 2023-01-10
TW202417497A (zh) 2024-05-01
JP7759417B2 (ja) 2025-10-23
EA201890928A1 (ru) 2018-09-28
JP2024026230A (ja) 2024-02-28
MX2023000738A (es) 2023-02-13
UY36942A (es) 2017-05-31
CO2018003852A2 (es) 2018-07-10
JP7165225B2 (ja) 2022-11-02
IL258448B2 (en) 2023-08-01
HRP20220426T8 (hr) 2022-06-10
IL316563A (en) 2024-12-01
CY1125102T1 (el) 2024-02-16
US10023644B2 (en) 2018-07-17
ES2908574T3 (es) 2022-05-03
MX2018004531A (es) 2018-09-12
CL2018000946A1 (es) 2018-12-14
IL258448B1 (en) 2023-04-01
DK3362477T3 (da) 2022-03-07
TW202216785A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
PT3362477T (pt) Proteínas de ligação a antigénio que ativam o recetor de leptina
IL263834A (en) Anti-pd-l1 antibodies
HUE051700T2 (hu) Anti-PD-1 antitestek
EP3481869A4 (en) ANTI-CD73 ANTIBODIES
DK3344654T3 (da) Anti-lag-3-antistoffer
IL263329B (en) Lysine conjugated immunoglobulins
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
IL256099A (en) Antibody
HUE060878T2 (hu) Anti-transztiretin antitestek
EP3643932A4 (en) LINKAGE MECHANISM
DK3250593T3 (da) Anti-transthyretin-antistoffer
EP3319983C0 (en) TAU LINKING ANTIBODIES
BR112016022040A2 (pt) aparelho de fixação.
KR102423233B9 (ko) 맞춤형 시설
PL3538554T3 (pl) Białka wiążące antygen, które antagonizują receptor leptyny
EP3324237A4 (en) LIGHT-SENSITIVE RESIN COMPOSITION
EP3491255A4 (en) IMPROVED TELESCOPIC MECHANISM
IL257368A (en) Antibody
DK3484921T3 (da) Anti-IL-22R antistoffer
DK3452515T3 (da) Her-2-bindende antistoffer
DK3249953T3 (da) Standardfikstur til en standardøresnegl
EP3470927A4 (en) TONER
EP3469003A4 (en) ANTI-PRL3 ANTIBODIES
DK3448420T3 (da) Anti-notch3-antistof
UA35277S (uk) Пробка